The solution leverages Google Cloud's Vertex (NASDAQ:VRTX) AI and BigQuery to provide ... with strategic partnerships with NVIDIA (NASDAQ:NVDA) and Dell (NYSE:DELL) enhancing the offering.

Dividend income is often overlooked amid gyrations in the stock market. But dividends are an important element of return. Dividend income accounted for 42% of the total return of the S&P 500 ...

The solution leverages Google Cloud’s Vertex (NASDAQ:VRTX) AI and BigQuery to provide AI-driven insights ... with strategic partnerships with NVIDIA (NASDAQ:NVDA) and Dell (NYSE:DELL) enhancing the ...

With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston, Massachusetts-based company engages in developing and ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

We're cautious about Vertex Pharmaceuticals. Here are three reasons why we avoid VRTX and a stock we'd rather own. Founded in 1989 to focus on a broad range of diseases, Vertex Pharmaceuticals ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $525.00. The company’s shares closed yesterday at $486.22.

Vertex Pharmaceuticals (NASDAQ:VRTX) ended a four-day winning streak on Thursday after UnitedHealth (NYSE:UNH) placed its new pain medication Journavx in a less favorable Tier 3 coverage in two ...

Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $445.00. The company’s shares closed ...

Great. Well thanks very much, everyone, for joining us for our next session with Vertex. My name is Dave Risinger. For those of you who don't know me, I cover Diversified Biopharmaceuticals. And ...